Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the P/S ratio high or low?
The P/S ratio of 0.45 is in line with its estimated 5-year average of 0.47, near the low end of its estimated 5-year range (0.26–3.10).
As of 2026-10-06T16:37:24.849Z. 10.37% below its estimated 12-month average of 0.50.
Calculation as of: 2026-10-06T16:37:24.849Z.
Quote observation: 2026-10-06T16:32:48.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cb51854f5b6e3a7e5b706ce3fddb8e5618a295b9891c132556284ed892856c50
Current P/S: FMP quote market capitalization / TTM revenue. Historical estimates use price and reported weighted-average shares; daily points use adjusted close × quarterly weighted-average shares / TTM revenue. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
0.45
PS RATIO AVG TTM
0.50
PS RATIO AVG 3Y
0.48
PS RATIO AVG 5Y
0.47
PS RATIO AVG 10Y
N/A
PS RATIO AVG 15Y
N/A
PS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-10.37%
CURRENT VS 3Y AVG
-6.69%
CURRENT VS 5Y AVG
-3.26%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
4.19
median of 510 covered companies
CURRENT VS SECTOR MEDIAN
-89.25%
vs the sector median at left
Market Cap
$242.54M
PS Ratio
57.53
TTM Avg
46.85
3Y Avg
41.58
5Y Avg
41.58
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| High Tide Inc. (HITI) | $236.81M | 0.45 | 0.50 | 0.48 | 0.47 |
| SIGA Technologies, Inc. (SIGA)vs › | $238.48M | 4.44 | 3.23 | 4.18 | 4.64 |
| InflaRx N.V. (IFRX)vs › | $238.97M | N/A | 1866.99 | 1234.73 | 1234.73 |
| Akebia Therapeutics, Inc. (AKBA)vs › | $237.44M | 1.08 | 1.71 | 2.09 | 1.59 |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $242.54M | 57.53 | 46.85 | 41.58 | 41.58 |
| MacroGenics, Inc. (MGNX)vs › | $233.59M | 1.39 | 1.23 | 3.39 | 3.84 |
| BioAge Labs Inc. (BIOA)vs › | $233.31M | 22.53 | 76.33 | 78.08 | 78.08 |
| Invivyd, Inc. (IVVD)vs › | $241.87M | 4.14 | 5.57 | 10.86 | 10.86 |
| Galectin Therapeutics Inc. (GALT)vs › | $243.34M | N/A | N/A | N/A | N/A |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $242.34M | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
Reported statement amounts were converted from CAD to USD using the stored FMP exchange-rate calculation.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q4 FY2025Period ended 2025-10-31 | $117,019,715 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-01-29 |
| Q1 FY2026Period ended 2026-01-31 | $131,081,827 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-17 |
| Q2 FY2026Period ended 2026-04-30 | $131,908,067 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-06-15 |
| Q3 FY2026Period ended 2026-07-31 | $143,304,423 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-09-14 |
| TTM revenue | $523,314,033 |
Current P/S: $236,810,124 market capitalization ÷ $523,314,033 TTM revenue = 0.45x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T16:32:48.000Z. Latest revenue period ended 2026-07-31.
At 0.45, P/S is below its estimated 8-year median — higher than 31% of readings in its estimated 8-year history.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
estimated 8-year low
0.26
median
0.57
estimated 8-year high
9.83
P/S Ratio
0.45
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PS RATIO |
|---|---|
| 2026-10-05 | 0.49 |
| 2026-10-02 | 0.48 |
| 2026-10-01 | 0.48 |
| 2026-09-30 | 0.49 |
| 2026-09-29 | 0.51 |
| 2026-09-28 | 0.51 |
| 2026-09-25 | 0.50 |
| 2026-09-24 | 0.49 |
| 2026-09-23 | 0.49 |
| 2026-09-22 | 0.50 |
| 2026-09-21 | 0.48 |
| 2026-09-18 | 0.47 |
| 2026-09-17 | 0.48 |
| 2026-09-16 | 0.49 |
| 2026-09-15 | 0.46 |
| 2026-09-14 | 0.47 |
| 2026-09-11 | 0.46 |
| 2026-09-10 | 0.46 |
| 2026-09-09 | 0.46 |
| 2026-09-08 | 0.48 |
| 2026-09-04 | 0.46 |
| 2026-09-03 | 0.45 |
| 2026-09-02 | 0.45 |
| 2026-09-01 | 0.45 |
| 2026-08-31 | 0.45 |
| 2026-08-28 | 0.45 |
| 2026-08-27 | 0.46 |
| 2026-08-26 | 0.45 |
| 2026-08-25 | 0.46 |
| 2026-08-24 | 0.44 |
| 2026-08-21 | 0.44 |
| 2026-08-20 | 0.44 |
| 2026-08-19 | 0.44 |
| 2026-08-18 | 0.43 |
| 2026-08-17 | 0.42 |
| 2026-08-14 | 0.42 |
| 2026-08-13 | 0.42 |
| 2026-08-12 | 0.42 |
| 2026-08-11 | 0.42 |
| 2026-08-10 | 0.41 |
| 2026-08-07 | 0.41 |
| 2026-08-06 | 0.41 |
| 2026-08-05 | 0.41 |
| 2026-08-04 | 0.41 |
| 2026-08-03 | 0.39 |
| 2026-07-31 | 0.38 |
| 2026-07-30 | 0.39 |
| 2026-07-29 | 0.37 |
| 2026-07-28 | 0.37 |
| 2026-07-27 | 0.38 |
| 2026-07-24 | 0.39 |
| 2026-07-23 | 0.39 |
| 2026-07-22 | 0.39 |
| 2026-07-21 | 0.40 |
| 2026-07-20 | 0.39 |
| 2026-07-17 | 0.40 |
| 2026-07-16 | 0.38 |
| 2026-07-15 | 0.39 |
| 2026-07-14 | 0.39 |
| 2026-07-13 | 0.39 |
| 2026-07-10 | 0.40 |
| 2026-07-09 | 0.40 |
| 2026-07-08 | 0.40 |
| 2026-07-07 | 0.40 |
| 2026-07-06 | 0.41 |
| 2026-07-02 | 0.41 |
| 2026-07-01 | 0.42 |
| 2026-06-30 | 0.41 |
| 2026-06-29 | 0.41 |
| 2026-06-26 | 0.40 |
| 2026-06-25 | 0.40 |
| 2026-06-24 | 0.40 |
| 2026-06-23 | 0.40 |
| 2026-06-22 | 0.41 |
| 2026-06-18 | 0.42 |
| 2026-06-17 | 0.43 |
| 2026-06-16 | 0.45 |
| 2026-06-15 | 0.43 |
| 2026-06-12 | 0.44 |
| 2026-06-11 | 0.45 |
| 2026-06-10 | 0.44 |
| 2026-06-09 | 0.45 |
| 2026-06-08 | 0.45 |
| 2026-06-05 | 0.44 |
| 2026-06-04 | 0.46 |
| 2026-06-03 | 0.45 |
| 2026-06-02 | 0.46 |
| 2026-06-01 | 0.47 |
| 2026-05-29 | 0.47 |
| 2026-05-28 | 0.48 |
| 2026-05-27 | 0.46 |
| 2026-05-26 | 0.45 |
| 2026-05-22 | 0.46 |
| 2026-05-21 | 0.47 |
| 2026-05-20 | 0.46 |
| 2026-05-19 | 0.46 |
| 2026-05-18 | 0.45 |
| 2026-05-15 | 0.46 |
| 2026-05-14 | 0.46 |
| 2026-05-13 | 0.46 |
| 2026-05-12 | 0.47 |
| 2026-05-11 | 0.48 |
| 2026-05-08 | 0.48 |
| 2026-05-07 | 0.48 |
| 2026-05-06 | 0.48 |
| 2026-05-05 | 0.46 |
| 2026-05-04 | 0.47 |
| 2026-05-01 | 0.47 |
| 2026-04-30 | 0.47 |
| 2026-04-29 | 0.46 |
| 2026-04-28 | 0.48 |
| 2026-04-27 | 0.49 |
| 2026-04-24 | 0.48 |
| 2026-04-23 | 0.46 |
| 2026-04-22 | 0.50 |
| 2026-04-21 | 0.46 |
| 2026-04-20 | 0.48 |
| 2026-04-17 | 0.47 |
| 2026-04-16 | 0.46 |
| 2026-04-15 | 0.48 |
| 2026-04-14 | 0.45 |
| 2026-04-13 | 0.45 |
| 2026-04-10 | 0.45 |
| 2026-04-09 | 0.44 |
| 2026-04-08 | 0.45 |
| 2026-04-07 | 0.44 |
| 2026-04-06 | 0.45 |
| 2026-04-02 | 0.44 |
| 2026-04-01 | 0.44 |
| 2026-03-31 | 0.44 |
| 2026-03-30 | 0.43 |
| 2026-03-27 | 0.43 |
| 2026-03-26 | 0.44 |
| 2026-03-25 | 0.44 |
| 2026-03-24 | 0.43 |
| 2026-03-23 | 0.44 |
| 2026-03-20 | 0.43 |
| 2026-03-19 | 0.45 |
| 2026-03-18 | 0.47 |
| 2026-03-17 | 0.52 |
| 2026-03-16 | 0.52 |
| 2026-03-13 | 0.51 |
| 2026-03-12 | 0.50 |
| 2026-03-11 | 0.51 |
| 2026-03-10 | 0.51 |
| 2026-03-09 | 0.50 |
| 2026-03-06 | 0.51 |
| 2026-03-05 | 0.52 |
| 2026-03-04 | 0.51 |
| 2026-03-03 | 0.52 |
| 2026-03-02 | 0.52 |
| 2026-02-27 | 0.52 |
| 2026-02-26 | 0.54 |
| 2026-02-25 | 0.53 |
| 2026-02-24 | 0.53 |
| 2026-02-23 | 0.51 |
| 2026-02-20 | 0.52 |
| 2026-02-19 | 0.50 |
| 2026-02-18 | 0.49 |
| 2026-02-17 | 0.49 |
| 2026-02-13 | 0.48 |
| 2026-02-12 | 0.48 |
| 2026-02-11 | 0.48 |
| 2026-02-10 | 0.49 |
| 2026-02-09 | 0.50 |
| 2026-02-06 | 0.49 |
| 2026-02-05 | 0.47 |
| 2026-02-04 | 0.48 |
| 2026-02-03 | 0.47 |
| 2026-02-02 | 0.47 |
| 2026-01-30 | 0.46 |
| 2026-01-29 | 0.53 |
| 2026-01-28 | 0.54 |
| 2026-01-27 | 0.54 |
| 2026-01-26 | 0.55 |
| 2026-01-23 | 0.56 |
| 2026-01-22 | 0.57 |
| 2026-01-21 | 0.57 |
| 2026-01-20 | 0.56 |
| 2026-01-16 | 0.56 |
| 2026-01-15 | 0.55 |
| 2026-01-14 | 0.57 |
| 2026-01-13 | 0.59 |
| 2026-01-12 | 0.59 |
| 2026-01-09 | 0.58 |
| 2026-01-08 | 0.59 |
| 2026-01-07 | 0.59 |
| 2026-01-06 | 0.59 |
| 2026-01-05 | 0.60 |
| 2026-01-02 | 0.61 |
| 2025-12-31 | 0.58 |
| 2025-12-30 | 0.57 |
| 2025-12-29 | 0.59 |
| 2025-12-26 | 0.61 |
| 2025-12-24 | 0.62 |
| 2025-12-23 | 0.61 |
| 2025-12-22 | 0.61 |
| 2025-12-19 | 0.61 |
| 2025-12-18 | 0.61 |
| 2025-12-17 | 0.60 |
| 2025-12-16 | 0.63 |
| 2025-12-15 | 0.60 |
| 2025-12-12 | 0.64 |
| 2025-12-11 | 0.58 |
| 2025-12-10 | 0.55 |
| 2025-12-09 | 0.55 |
| 2025-12-08 | 0.54 |
| 2025-12-05 | 0.55 |
| 2025-12-04 | 0.57 |
| 2025-12-03 | 0.58 |
| 2025-12-02 | 0.58 |
| 2025-12-01 | 0.57 |
| 2025-11-28 | 0.57 |
| 2025-11-26 | 0.58 |
| 2025-11-25 | 0.56 |
| 2025-11-24 | 0.55 |
| 2025-11-21 | 0.57 |
| 2025-11-20 | 0.57 |
| 2025-11-19 | 0.59 |
| 2025-11-18 | 0.60 |
| 2025-11-17 | 0.58 |
| 2025-11-14 | 0.59 |
| 2025-11-13 | 0.63 |
| 2025-11-12 | 0.65 |
| 2025-11-11 | 0.65 |
| 2025-11-10 | 0.66 |
| 2025-11-07 | 0.65 |
| 2025-11-06 | 0.63 |
| 2025-11-05 | 0.66 |
| 2025-11-04 | 0.66 |
| 2025-11-03 | 0.67 |
| 2025-10-31 | 0.68 |
| 2025-10-30 | 0.67 |
| 2025-10-29 | 0.68 |
| 2025-10-28 | 0.69 |
| 2025-10-27 | 0.71 |
| 2025-10-24 | 0.73 |
| 2025-10-23 | 0.68 |
| 2025-10-22 | 0.68 |
| 2025-10-21 | 0.73 |
| 2025-10-20 | 0.73 |
| 2025-10-17 | 0.73 |
| 2025-10-16 | 0.75 |
| 2025-10-15 | 0.78 |
| 2025-10-14 | 0.76 |
| 2025-10-13 | 0.74 |
| 2025-10-10 | 0.75 |
| 2025-10-09 | 0.78 |
| 2025-10-08 | 0.78 |
| 2025-10-07 | 0.79 |
| 2025-10-06 | 0.78 |
| 2025-10-03 | 0.78 |
| 2025-10-02 | 0.79 |
| 2025-10-01 | 0.79 |
| 2025-09-30 | 0.79 |
| 2025-09-29 | 0.82 |
| 2025-09-26 | 0.77 |
| 2025-09-25 | 0.82 |
| 2025-09-24 | 0.85 |
| 2025-09-23 | 0.79 |
Showing the most recent 260 of 1,929 data points. The chart above shows the full history.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.